What are the treatment options for Peyronie's syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Treatment for Peyronie's syndrome should prioritize intralesional collagenase clostridium histolyticum (Xiaflex) as the first-line therapy for patients with curvature between 30° and 90° and intact erectile function, due to its moderate recommendation and evidence strength grade B, as established by the AUA guideline 1.

Overview of Treatment Options

Treatment options for Peyronie's disease include both non-surgical and surgical approaches, depending on disease severity and phase.

  • In the acute phase (first 6-12 months), oral medications like pentoxifylline, colchicine, or potassium para-aminobenzoate may be prescribed to reduce inflammation and plaque formation, though evidence for their effectiveness is limited.
  • Injectable treatments directly into the plaque include collagenase clostridium histolyticum (Xiaflex) and verapamil injections.
  • Non-drug approaches include penile traction therapy devices worn for several hours daily over months to gradually stretch and remodel the plaque.

Surgical Options

For stable disease with significant curvature or erectile dysfunction, surgical options include:

  • Plication procedures to straighten the penis
  • Plaque incision or excision with grafting for more severe cases
  • Penile prosthesis implantation for men with both Peyronie's and erectile dysfunction

Considerations for Treatment Choice

Treatment choice depends on disease phase, curvature severity, erectile function, and patient preferences, with best results typically achieved through a combination of approaches under urological specialist care, as noted in the AUA guideline 1.

Recent Guidelines and Recommendations

Recent guidelines, such as those from the AUA, emphasize the importance of counseling patients about potential adverse events associated with treatments like intralesional verapamil and intralesional interferon α-2b 1.

Additional Considerations

For patients with erectile dysfunction, options like vacuum erection devices, intracavernosal injection, and intraurethral suppositories may be considered, with referral to a sexual medicine clinician recommended for second- and third-line therapies, as noted in updates to the NCCN Guidelines for survivorship 1.

From the Research

Treatment Options for Peyronie's Syndrome

The treatment options for Peyronie's syndrome can be categorized into several approaches, including:

  • Conservative therapy, which is the most common recommendation during the active phase of the disease 2
  • Oral and topical medications, such as vitamin E and para-aminobenzoate (Potaba), although their efficacy is not well established 3, 4
  • Intralesional injection therapies, including interferon alpha-2B, verapamil, and collagenase, which have shown some benefit in decreasing penile pain and curvature 3, 4, 5
  • External energy therapies, such as extracorporeal shock wave lithotripsy, which may improve penile pain but has mixed results for penile curvature 3, 5
  • Surgical interventions, including tunical plication, plaque incision or excision with or without grafting, and penile prosthesis implantation, which are typically reserved for the passive phase of the disease or for patients who do not respond to conservative therapy 2, 6

Considerations for Treatment

When considering treatment options for Peyronie's syndrome, it is essential to:

  • Evaluate the extent of the patient's symptoms and bother 2
  • Discuss treatment goals, therapeutic options, and expectations with the patient 2
  • Consider the disease phase, with conservative therapy typically recommended during the active phase and more invasive treatments reserved for the passive phase 2
  • Be aware of the potential side effects and complications associated with each treatment option, such as penile shortening, sensation changes, and erectile dysfunction 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Peyronie's disease: what do we know and how do we treat it?

The Canadian journal of urology, 2020

Research

[Pathophysiology and management of Peyronie's disease in adult patients: an update].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2010

Research

Medical management of Peyronie's disease.

Journal of andrology, 2009

Research

Peyronie's disease: Contemporary evaluation and management.

International journal of urology : official journal of the Japanese Urological Association, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.